Improved air quality may slow cognitive decline in older women
Feb 09, 2022
No differences in associations were seen according to age, geographic region, education, apolipoprotein E e4 genotypes or cardiovascular risk factors.
Innovation funders looking to support mature tech projects in senior living space as part of new initiative
By
Aaron Dorman
Nov 03, 2023
Health tech orgs are collaborating on a new funding program, envisAGE, targeted at near-ready startups for senior living innovations.
Top 10 safety and security considerations when designing a senior living community
By
Chad Ulman
Apr 30, 2018
Giving attention to the safety and security of your senior living community will have a powerful, positive effect on resident satisfaction.
Get smart about brain health
By
Catherine O’Brien, Ph.D.
Mar 02, 2015
Activity directors and lifestyle coordinators across the country are trying to find the best solutions for residents who request “brain games” out of a desire to improve their memory and sharpen...
Second death in trial of experimental Alzheimer’s drug raising concerns
Nov 29, 2022
Doctors suspect that by stripping away amyloid deposits, lecanemab weakens blood vessels and leaves them vulnerable to bleeds.
Intranasal insulin may have pro-cognitive benefits
Jun 30, 2023
Improvement in global cognition was seen for patients with Alzheimer’s disease/mild cognitive impairment, but no effects were seen for healthy individuals or other patient populations.
Hypertension, type 2 diabetes contribute to brain changes in Puerto Rican seniors
Apr 01, 2022
A high prevalence of hypertension and type 2 diabetes was seen among the Puerto Rican cohort; those with both have deteriorating patterns in major white matter tracts.
Neuroimaging measures linked to stages of memory impairment
Mar 04, 2022
The presence of Alzheimer’s disease pathology is related to Stages of Objective Memory Impairment in cognitively unimpaired older adults.
Solanezumab does not slow cognitive decline in preclinical Alzheimer’s disease
Jul 19, 2023
The mean change in Preclinical Alzheimer Cognitive Composite score not significantly different at 240 weeks with solanezumab or placebo.
Minor neuropsychological deficits indicate risk for progression to Alzheimer’s disease
Oct 13, 2023
For patients with subjective cognitive decline, those with minor neuropsychological deficits have increased cognitive decline and a risk for progression to mild cognitive impairment.